IN-LICENSED TECHNOLOGY - Skinvisible (Details) - Skinvisible Licensing Agreement - USD ($) $ in Millions |
1 Months Ended | ||
|---|---|---|---|
Oct. 31, 2019 |
Sep. 30, 2025 |
Dec. 31, 2024 |
|
| IN-LICENSED TECHNOLOGY | |||
| License fee | $ 1 | ||
| Percentage of revenues to be paid | 25.00% | ||
| Amount of payment to be made | $ 5 | ||
| Milestone or royalty obligations due | $ 0 | $ 0 |
| X | ||||||||||
- Definition Represents the percentage of revenues to be paid under asset acquisition. No definition available.
|
| X | ||||||||||
- Definition Amount of milestone or royalty obligations payable. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of liability recognized from contingent consideration in asset acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|